Andros Pharmaceuticals Co (ROCO:6917) Equity-to-Asset : 0.89 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Andros Pharmaceuticals Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Andros Pharmaceuticals Co's Total Stockholders Equity for the quarter that ended in Dec. 2023 was NT$471.11 Mil. Andros Pharmaceuticals Co's Total Assets for the quarter that ended in Dec. 2023 was NT$529.15 Mil. Therefore, Andros Pharmaceuticals Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.89.

The historical rank and industry rank for Andros Pharmaceuticals Co's Equity-to-Asset or its related term are showing as below:

ROCO:6917' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.57 Med: 0.68 Max: 0.89
Current: 0.89

During the past 5 years, the highest Equity to Asset Ratio of Andros Pharmaceuticals Co was 0.89. The lowest was 0.57. And the median was 0.68.

ROCO:6917's Equity-to-Asset is ranked better than
83.35% of 1556 companies
in the Biotechnology industry
Industry Median: 0.67 vs ROCO:6917: 0.89

Andros Pharmaceuticals Co Equity-to-Asset Historical Data

The historical data trend for Andros Pharmaceuticals Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Andros Pharmaceuticals Co Equity-to-Asset Chart

Andros Pharmaceuticals Co Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Equity-to-Asset

0.68

0.59

0.57

0.85

0.89

Andros Pharmaceuticals Co Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Equity-to-Asset	Get a 7-Day Free Trial			0.57	0.79	0.85	0.85	0.89

Competitive Comparison of Andros Pharmaceuticals Co's Equity-to-Asset

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Andros Pharmaceuticals Co's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Equity-to-Asset falls into.

Andros Pharmaceuticals Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Andros Pharmaceuticals Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	471.107	/	529.146
	=	0.89

Andros Pharmaceuticals Co's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	471.107	/	529.146
	=	0.89

Andros Pharmaceuticals Co (ROCO:6917) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Andros Pharmaceuticals Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Andros Pharmaceuticals Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Andros Pharmaceuticals Co (ROCO:6917) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Andros Pharmaceuticals Co Ltd (ROCO:6917) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261

Website

http://www.androspharma.com

Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).

Andros Pharmaceuticals Co (ROCO:6917) Headlines

No Headlines